Experimental therapy challenges standard care in advanced gastric cancer trial
NCT ID NCT07103668
Summary
This study compares an experimental treatment called IMC002 against standard treatments for advanced stomach cancer that has spread and cannot be surgically removed. It's for patients whose cancer has a specific marker called CLDN18.2 and who have already tried at least two other treatments. The goal is to see if IMC002 can better control cancer growth and extend survival compared to currently available options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese PLA General Hospital, Beijing
RECRUITINGBeijing, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.